Akari Therapeutics (NASDAQ:AKTX) Earns Buy Rating from Analysts at Maxim Group
Maxim Group started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $5.00 price target on the biopharmaceutical company’s stock. Separately, Wall Street Zen assumed coverage on shares of Akari Therapeutics in a report on Wednesday, May […]
More Stories
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....
Who is Jonathan Joly? Age, Marriage, and Net Worth in 2026
If you like to scroll on social media, the chances of you witnessing Jonathan Joly are high. Are you also...
Rory McIlroy Wins Back-to-Back Masters Titles to Join Jack Nicklaus, Nick Faldo, and Tiger Woods
By The Associated Press AUGUSTA, Ga.—Rory McIlroy joined more elite company Sunday at the Masters when he pulled away with...
At Least 30 Dead in Stampede at Haiti’s Historic Laferriere Citadel
By Reuters At least 30 people were killed on Saturday in a stampede in the northern countryside of Haiti, authorities...
Oil Prices Rise After US Announces Blockade on Iranian Ports
By Naveen Athrappully Brent crude oil futures prices surged late Sunday following the United States threatening to block Iranian ports...
Eric Swalwell Ends Bid for California Governor Amid Sexual Misconduct Allegations
By Joseph Lord Rep. Eric Swalwell (D-Calif.) suspended his bid for California governor on Sunday after reports emerged accusing the...